Clinical Trials
106 trialsNCT07007182 2026-05-01
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07556640 2026-04-29
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
Ruijin Hospital
Phase 2 Recruiting
NCT06576921 2026-04-23
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Xijing Hospital
Phase 2 Recruiting
NCT05184803 2026-04-07
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
Asan Medical Center
Phase 2 Recruiting
NCT07515625 2026-04-07
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT07492615 2026-03-25
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Recruiting
NCT06519591 2026-02-18
Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
Ruijin Hospital
Phase 2 Recruiting
NCT07374250 2026-01-28
Huaxi
Sichuan University
Phase 2 Not yet recruiting
NCT07366528 2026-01-26
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital
Phase 3 Recruiting
NCT03013010 2025-12-08
PREACT
Shanghai Cancer Hospital, China
Phase 3 Completed
NCT07194005 2025-09-26
Remission
Fudan University
Phase 2 Recruiting
NCT06732856 2025-07-28
NEO-CLAUD
Asan Medical Center
Phase 1/2 Recruiting
NCT07025889 2025-06-18
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Ruijin Hospital
Phase 1/2 Recruiting
NCT07018063 2025-06-12
YOUNG-NEOS
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT05593458 2025-04-09
TACTIC
Zhejiang University
Phase 3 Recruiting
NCT06914687 2025-04-06
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT04863430 2025-02-21
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
Phase 2 Withdrawn
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
NCT02867839 2024-12-03
RESCUE-GC
Peking University Cancer Hospital & Institute
Phase 3 Terminated
NCT06555471 2024-08-15
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06487429 2024-07-05
Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06454435 2024-06-12
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06451211 2024-06-11
Neo-ICEBOAT
Sun Yat-sen University
Phase 2 Recruiting
NCT06447636 2024-06-07
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06385873 2024-05-13
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06341595 2024-04-02
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04694183 2024-02-07
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
The First Hospital of Jilin University
Phase 2 Completed
NCT06213519 2024-01-19
HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis
Sichuan University
Phase 2 Not yet recruiting
NCT06194981 2024-01-12
Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage
The First Affiliated Hospital of Zhengzhou University
Unknown
NCT03607656 2023-12-18
CHANGE
Shanghai University of Traditional Chinese Medicine
Phase 2/3 Completed
NCT04999332 2023-11-15
LOTS
National Cheng-Kung University Hospital
Phase 2 Unknown
NCT02338518 2023-09-29
SVOSA
Jinling Hospital, China
Phase 3 Unknown
NCT04250948 2023-08-01
Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT05948449 2023-07-17
To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Sichuan University
Phase 2 Unknown
NCT04267549 2023-07-06
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05853172 2023-05-10
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04819971 2023-04-25
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05687357 2023-04-19
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05052931 2023-04-13
Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer
Xijing Hospital
Phase 2 Unknown
NCT04047953 2023-04-05
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
Peking University Cancer Hospital & Institute
Phase NA Recruiting
NCT05769725 2023-03-15
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
RenJi Hospital
Phase 2 Unknown
NCT02191566 2022-12-08
SOHUG
Kangbuk Samsung Hospital
Phase 2 Terminated
NCT05627414 2022-11-25
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03001726 2022-05-06
To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.
Shanghai Zhongshan Hospital
Unknown
NCT05228743 2022-02-08
Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT05204173 2022-01-24
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
Ruijin Hospital
Phase 2 Unknown
NCT03801668 2022-01-04
Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
Huazhong University of Science and Technology
Phase 3 Unknown
NCT05111444 2021-11-08
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Fudan University
Phase 2 Unknown